AXIM BIOTECHNOLOGIES AXIM news, videos and press releases
For more news please use our advanced search feature.
AXIM BIOTECHNOLOGIES AXIM - More news...
AXIM BIOTECHNOLOGIES AXIM - More news...
- VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
- AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
- AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
- Update: AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
- AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
- AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
- AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
- AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
- AXIM® Biotechnologies Files Provisional Patent on Novel Methodology for Use in Optical Diagnostic Assay Manufacturing
- AXIM Biotechnologies Files Patent on Fentanyl Neutralizing Antibody Test, Applies for DEA License to Work With Controlled Substance
- Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc. Moves Forward on Oral Healthcare Line With Cannabinoid Product Supply Agreement
- Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
- Medical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids
- Medical Marijuana, Inc. Subsidiary Kannaway® Places Significant Initial Purchase Order for Major Investment Company AXIM® Biotechnologies CBD Chewing Gum
- Medical Marijuana, Inc. Reports Third Quarter 2017 Financial Results and Operational Highlights: Shows Record 255% Gross Profit Increase
- Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome
- Medical Marijuana, Inc. Major Investment AXIM Biotech Files Patent On Controlled Release Chewing Gum To Provide Opioid Addiction Treatment
- SeeThruEquity Initiates Coverage On Medical Marijuana, Inc. Investment Company AXIM Biotech (OTC: AXIM) With A Target Price Of $17.00
- Medical Marijuana, Inc. Reports Year End 2016 Financial Results and Operational Highlights - Product Sales by Quarter Increased 66% Q1-Q4
- Medical Marijuana, Inc. Reports Year End 2016 Financial Results and Operational Highlights - Product Sales by Quarter Increased 66% Q1-Q4
- Medical Marijuana, Inc. Major Investment AXIM Biotech Enters Term Sheet Agreement With U.S. API Company To Develop Bioequivalent Product To Marinol
- Medical Marijuana, Inc. Investment AXIM Biotech Retains Ora To Manage Upcoming Product Development And Clinical Trials On Glaucoma And Dry Eye Indications
- Medical Marijuana, Inc. Investment AXIM® Biotech Announces Enrolled Patients Begin Phase II Trial For The Treatment Of Irritable Bowel Syndrome (IBS) With CanChew Plus® Cannabidiol (CBD) Chewing Gum
- AXIM Biotech Holds Annual Board Meeting
- Medical Marijuana, Inc. Investment AXIM® Biotech Enters IBS Clinical Trial With CBD Chewing Gum
- AXIM® Biotech Enters IBS Clinical Trial for CanChew CBD Chewing Gum
- AXIM Biotech Attends Biotech Showcase and J.P. Morgan Healthcare Conferences in San Francisco
- AXIM® Biotech Receives Positive PK Data Results for CanChew Plus® CBD Gum
- AXIM® Biotech Expands Advisory Board to Broaden the Development of Cannabinoids' Therapeutic Indications
- Axim® Biotech Announces Addition of World-Renowned Opthamologist to Advisory Board
